Cargando…
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
BACKGROUND: Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO)...
Autores principales: | Noguchi, Masanori, Moriya, Fukuko, Suekane, Shigetaka, Ohnishi, Rei, Matsueda, Satoko, Sasada, Tetsuro, Yamada, Akira, Itoh, Kyogo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882108/ https://www.ncbi.nlm.nih.gov/pubmed/24373380 http://dx.doi.org/10.1186/1471-2407-13-613 |
Ejemplares similares
-
Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017) -
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020) -
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018) -
Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015) -
Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)